7 unknown, 5 completed, 1 not yet recruiting, 1 recruiting. 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Unknown 7, Completed 5, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow icotinib: new trials by email Literature Review of icotinib trials Research Report on icotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations Icotinib, Rezivertinib, Ensartinib - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 270 | 2025-05-01 | 2025-05-06 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo - Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 570 | 2023-03-28 | 2023-09-22 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC Anlotinib, Icotinib - Non Small Cell Lung Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 206 | 2021-03-12 | 2021-03-15 |
| Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. Icotinib - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 70 | 2019-07-01 | 2019-06-20 |
| A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy Icotinib, SRS/WBRT/HA-WBRT/SMART - Non Small Cell Lung Cancer, Brain Metastases | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 296 | 2018-07-20 | 2019-08-15 |
| First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation icotinib, Chemotherapy, Radiotherapy - Non-small Cell Lung Cancer | Phase 3 | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 330 | 2016-06-01 | 2016-08-30 |
| Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation Icotinib, Chemotherapy - Non-small Cell Lung Cancer | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 320 | 2015-06-08 | 2021-07-20 |
| Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib, WBRT, HFSRS - Stage IV EGFR Mutated NSCL With Brain Metastases | Phase 3 | Unknown | Sichuan Provincial People's Hospital | 325 | 2015-03-01 | 2016-08-30 |
| Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Icotinib, Placebo - EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 124 | 2014-09-01 | 2018-07-16 |
| Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation 6-month Icotinib, 12-month icotinib - Lung Cancer | Phase 3 | Terminated | Sun Yat-sen University | 251 | 2014-01-01 | 2024-09-05 |
| Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma YiQiFang, YangYinFang, YiQiYangYinFang - Cancer | Phase 3 | Completed | Shanghai University of Traditional Chinese Medicine | 23 | 2013-03-01 | 2019-04-11 |
| Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients Icotinib, Chemotherapy - NSCLC | Phase 3 | Completed | Betta Pharmaceuticals Co., Ltd. | 296 | 2012-12-01 | 2019-07-05 |
| Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer whole brain radiation(WBI), Icotinib - Brain Metastasis, Non Small Cell Lung Cancer | Phase 3 | Completed | Guangdong Association of Clinical Trials | 176 | 2012-10-14 | 2017-03-01 |
| Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy icotinib - Non-small Cell Lung Cancer | Phase 3 | Completed | Betta Pharmaceuticals Co., Ltd. | 128 | 2010-03-01 | 2015-07-01 |
| Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients Icotinib, Gefitinib - Non-small Cell Lung Cancer | Phase 3 | Completed | Betta Pharmaceuticals Co., Ltd. | 399 | 2009-02-01 | 2014-02-14 |
Carcinoma, Non-Small-Cell Lung (9) · Brain Neoplasms (2) · Lung Neoplasms (2) · Adenocarcinoma (1) · Neoplasms (1)
Betta Pharmaceuticals Co., Ltd. (7) · Tianjin Medical University Cancer Institute and Hospital (2) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Guangdong Association of Clinical Trials (1) · Shanghai University of Traditional Chinese Medicine (1) · Sichuan Provincial People's Hospital (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Guangzhou Medical University (1)
China (12)
Caicun Zhou, MD (1) · Chen Ming (1) · Fenlai Tan, M.D./Ph.D. (1) · Jianxing He, MD (1) · Jinji Yang, MD (1) · Li Zhang, M.D. (1) · Ming Zeng, MD PhD (1) · Peng Chen, M.D. (1) · Shi Yuankai, M.D. (1) · Shun Lu, M.D. (1) · Si-Yu Wang, MD (1) · Yan Sun, M.D. (1) · Yan Sun, MD (1) · Yuan-Kai Shi, MD (1)
PMID 23948351, PMID 22112293, PMID 22967997, PMID 26599904, PMID 27619516, PMID 28734822, PMID 28945850, PMID 32606956, PMID 34280355, PMID 40421698, PMID 40866342, PMID 42660909